Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189345
Status:
COMPLETED
Last Update Posted:
2006-11-08
First Post:
2005-09-12
Brief Title:
Randomized Multicenter 2-Dose Level Open-Label Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody RemovabTM Anti-EpCAM x Anti-CD3 to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Sponsor:
AGO Study Group
Organization:
AGO Study Group
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-05
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2005-10
Completion Date Type:
None
First Submit Date:
2005-09-12
First Submit QC Date:
September 12 2005
Study First Post Date:
2005-09-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2006-11-07
Last Update Post Date:
2006-11-08
Last Update Post Date Type:
ESTIMATED